Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.
Related Posts
The Fed Is in no Rush to Cut Rates, Even if There Is a Weak Jobs Report
Fed officials have signaled that it will take more than one weak report to convince them that the labor market is deteriorating.
GM Cuts Profit Forecast by 20% and Says Auto Tariffs Will Cost It Billions
General Motors now expects to earn a lot less than it did before President Trump imposed 25% tariffs on imported cars and auto parts.
Hanford, a Contaminated Nuclear Site, It Set to Be Largest US Solar Farm
Plans to transform Hanford, which was integral to the nation’s nuclear arsenal after World War II, had just begun inching forward when President Trump started […]